3 stocks you can buy today for up to 70% less than Neil Woodford paid!

Should you snap up these Neil Woodford favourites at big discounts?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve been running my eye over ace investor Neil Woodford’s portfolios, looking for potential bargains. Here are three stocks you can buy today at up to 70% less than he paid.

Hedge fund attack

FTSE 250 firm Allied Minds (LSE: ALM) commercialises intellectual property coming out of US universities and government research labs, supporting its portfolio of businesses with capital, central management and shared services.

Woodford has bought a number of tranches of shares in Allied over the years, including in May 2015 when they were trading at around 600p (giving the company a market capitlisation of £1.3bn). The Woodford website published a bullish blog post on the company just prior to this purchase.

In September 2015, when the shares were 499p (market cap £1.1bn), Allied was attacked in a scathing report by New York hedge fund Kerrisdale Capital as “a dressed-up collection of high-risk, low-reward gambles that we believe has at least 70% downside.”

Woodford was unconcerned by the report and has continued to support Allied with further investment. The shares are currently 367p (market cap £794m). The Kerrisdale analysis has its flaws, but some of the issues it raised have left me uneasy. I’d suggest investors need to satisfy themselves that there’s no merit in Kerrisdale’s arguments before considering an investment in Allied.

Pipeline setback

Woodford more than doubled his stake in Circassia Pharmaceuticals (LSE: CIR) by participating in a fundraising at 288p (market cap £820m) in June 2015.

A year later, Circassia’s shares crashed on the failure of a phase III study of its flagship cat allergy vaccine. This led the company to put the development of its allergy portfolio on hold while awaiting results of a phase III study of its other advanced allergy vaccine — for house dust mites — in spring 2017.

Woodford posted his response to the disappointment, highlighting that Circassia has other “very attractive respiratory products both in the market and under development”, that it “remains very well-financed” and saying “we remain supportive shareholders and from here, we continue to see long-term value in the shares”.

Circassia was demoted from the FTSE 250 to the SmallCap index in September and its shares are currently trading at 84p (market cap £239m), which is 6.6 times forecast revenue for 2017. I’m inclined to think it wise to wait for the upcoming results of the house dust mites vaccine study before considering an investment here.

Speculative buy

Regenerative medical devices company Tissue Regenix (LSE: TRX) has neither come under attack by a hedge fund nor suffered a major pipeline setback. Woodford bought a big slug of shares in this AIM-listed company two years ago when they were trading at around 23p (market cap £150m). You can pick them up today at 17p (market cap £129m), so a 26% discount on share price and a 14% discount on market cap.

The company is valued at 7.7 times forecast revenue for 2017 and with another encouraging product update this morning, including prospects for rapid commercialisation, there is plenty of scope for upward revisions of analyst revenue forecasts in the coming year and beyond. Based on the quality of its products and the size of its potential markets, I rate Tissue Regenix as one of the more promising higher risk, speculative buys around today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »